The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is launching a Roundtable webinar series on digital devices for 2021. Presented by subject matter experts in the pharmaceutical sciences, this is a unique opportunity to learn about the latest research and regulatory trends focused on digital devices.
Want to learn what a Biomarker is?
Cambridge Consultants Joe Corrigan, head of business development for intelligent health and James Blakemore Ph.D., Senior Consultant, Strategy Group presented on the progression of digital biomarkers in clinical trials and beyond at IPAC-RS 2021.
The Progression of Digital Biomarkers in Clinical Trials and Beyond
As a developer of connected pharmaceutical aerosol devices, and beyond into diagnostics and industrial systems, Cambridge Consultants is well placed to observe the progression of industry trends in digital adoption and digital biomarkers. As digitisation takes hold, and access to healthcare-focused digital information management systems becomes more interconnected, there is greater scope for development of digital health solutions. Digital clinical trials improve patient access, recruitment and retention, can speed data collection and analytics and allows for precision interventions. Because of the high value of the segment, development of digital biomarkers has attracted investment from pharma, medical device and consumer device backgrounds. The overall trend is from digitisation of information toward transformation of the patient care paradigm through real-time diagnostics and molecular biomarkers with analytics that can be acted on by the patient or caregiver.
The Covid-19 pandemic has accelerated investment in the development of telehealth solutions and the development of decentralised clinical trials. From a technology perspective this means that connected systems have been a priority, allowing new entrants to gain a foothold with connectivity solutions. More precise, less invasive diagnostics, along with artificial intelligence/machine learning and edge compute platforms, are permitting data acquisition to progress from narrowband to broadband allowing greater insight to be derived from clinical trials and the potential for modified interventional strategies at the point of care.
Speakers:
- Joe Corrigan, head of business development for intelligent health, Cambridge Consultants
- James Blakemore Ph.D., Senior Consultant Strategy Group, Cambridge Consultants
Watch to learn more
Related content
